Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

Oct 03, 2019 — From IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA) held in Washington, DC October 2 – 6. TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that […]

Continue reading

Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

Sep 18, 2019 — Accelerate Diagnostics, Inc. recently highlighted the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019.   “We are thrilled with the results of these clinical studies, which provide further evidence of the clinical value of Pheno,” commented Dr. Romney Humphries, Chief Scientific Officer of […]

Continue reading

Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit

Aug 02, 2019 — Today we announced the release and CE marking of our latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices. The new CE-IVD Accelerate PhenoTest™ BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, and trimethoprim-sulfamethoxazole […]

Continue reading

University of Iowa Hospitals & Clinics announces adoption of Accelerate Pheno

Jan 16, 2019 — University of Iowa Hospitals & Clinics recently shared their adoption of the Accelerate Pheno™ system as a “new technology that helps diagnose and treat sepsis—a potentially life-threatening infection in the blood—faster than ever before.” Get the full story from UI Health Care Quick story excerpt: “Every hour counts,” explains Bradley Ford, MD, PhD, medical director […]

Continue reading

See all news

See the Latest data from IDWeek™

See the Latest data from ASM

Media kit

Media contact

Andy Chasteen

Company information

About the company
Our products

Digital assets

Enter your email address below for access to photos, logos and videos.

See Terms and Use Policy

Connect with us

  Like us on Facebook
  Follow us on Twitter
  See us on Linkedin
  Visit us on Google+

Upcoming Events
IDWeek 2019

October 2-6, 2019
Washington, DC

Learn more

AMCLI 2019

November 9-12, 2019
Palacongressi Di Rimini, IT

Learn more

FIS 2019

November 11-14, 2019
Edinburgh, Scotland

Learn more

Past Events
ASM Microbe 2019

June 20–24, 2019
San Francisco

Learn more


April 13-16, 2019
Amsterdam, Netherlands

Learn more

SCCM 2019

February 17-20, 2019
San Diego, California

Learn more


February 4 - 7, 2019
Dubai World Trade Centre, UAE

Learn more

RICAI 2018

December 17 - 18, 2018
Palais des Congrès de Paris

Learn more

AMCLI 2018

November 10 - 13, 2018
Palacongressi Di Rimini, IT

Learn more

Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.

These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.

Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.

See product labeling for instructions for use, warnings, and limitations specific to each product and region.

Okay, I understand. Show me the publications.